Metastatic Castrate-resistant Prostate (CRPC) Cancer Clinical Trial
Official title:
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
To assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire
n/a